Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Long-Term Investments (2019 - 2024)

Nurix Therapeutics (NRIX) has disclosed Long-Term Investments for 6 consecutive years, with $9.5 million as the latest value for Q3 2024.

  • On a quarterly basis, Long-Term Investments fell 4.15% to $9.5 million in Q3 2024 year-over-year; TTM through Aug 2024 was $9.5 million, a 4.15% decrease, with the full-year FY2023 number at $7.4 million, down 88.38% from a year prior.
  • Long-Term Investments was $9.5 million for Q3 2024 at Nurix Therapeutics, up from $9.4 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $137.2 million in Q4 2021 to a low of $7.4 million in Q4 2023.
  • A 5-year average of $59.3 million and a median of $51.5 million in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: skyrocketed 17862.45% in 2020, then tumbled 88.38% in 2023.
  • Nurix Therapeutics' Long-Term Investments stood at $90.9 million in 2020, then soared by 50.94% to $137.2 million in 2021, then tumbled by 53.44% to $63.9 million in 2022, then crashed by 88.38% to $7.4 million in 2023, then increased by 27.64% to $9.5 million in 2024.
  • Per Business Quant, the three most recent readings for NRIX's Long-Term Investments are $9.5 million (Q3 2024), $9.4 million (Q2 2024), and $10.3 million (Q1 2024).